Quantcast
Home > Quotes > MTEM

Molecular Templates, Inc. Common Stock (MTEM) Quote & Summary Data

MTEM 
$5.21
*  
0.34
6.98%
Get MTEM Alerts
*Delayed - data as of Aug. 14, 2018  -  Find a broker to begin trading MTEM now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
$ 4.91 / $ 5.66
1 Year Target
17
Today's High / Low
$ 5.24 / $ 4.81
Share Volume
81,131
50 Day Avg. Daily Volume
97,582
Previous Close
$ 4.87
52 Week High / Low
$ 13.25 / $ 4.611
Market Cap
140,985,742
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
1.49

Intraday Chart

Shares Traded

Share Volume:
81,131
50 Day Avg. Daily Volume:
97,582

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -0.84

Trading Range

The current last sale of $5.21 is 12.99% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 5.24 $ 13.25
 Low: $ 4.81 $ 4.611

Company Description (as filed with the SEC)

Molecular Templates, Inc., or Molecular, is a clinical-stage oncology company focused on the discovery and development of differentiated, targeted, biologic therapeutics for cancer. Molecular utilizes its proprietary biologic drug platform to design and generate engineered toxin bodies, or ETBs, which Molecular believes provide a differentiated mechanism of action that may be beneficial in patients resistant to currently available cancer therapeutics. ETBs use a genetically engineered version of the Shiga-like Toxin A subunit, or SLTA, a ribosome inactivating bacterial protein. In its wild-type form, SLT is thought to induce its own entry into a cell when proximal to the cell surface membrane, self-route to the cytosol, and enzymatically and irreversibly shut down protein synthesis via ribosome inactivation. SLTA is normally coupled to its cognate Shiga-like Toxin B subunit, or SLTB, to target the CD77 cell surface marker, a non-internalizing glycosphingolipid.  ... More ...  


Risk Grade

Where does MTEM fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 4.87
Open Date:
Aug. 14, 2018
Close Price:
$ 5.21
Close Date:
Aug. 14, 2018

Consensus Recommendation

Analyst Info